Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Core Points - Xilio Therapeutics, Inc. announced the grant of a non-qualified stock option to its newly hired Chief Legal Officer, Caroline Hensley, effective January 1, 2025 [1] - The stock option allows the purchase of 375,000 shares at an exercise price of $0.955 per share, which matches the closing price on December 31, 2024 [2] - The stock option has a ten-year term, with 25% vesting on the first anniversary of employment and the remaining 75% vesting in 36 equal monthly installments [2] - The grant is part of Xilio Therapeutics' 2022 Inducement Stock Incentive Plan and complies with Nasdaq Listing Rule 5635(c)(4) [3] Company Overview - Xilio Therapeutics is a clinical-stage biotechnology company focused on developing tumor-activated immuno-oncology therapies aimed at improving cancer treatment outcomes while minimizing systemic side effects [4] - The company utilizes a proprietary platform to advance a pipeline of novel I-O molecules, including tumor-activated cytokines, antibodies, bispecifics, and immune cell engagers [4]